Advancing DD01, a Ratio Optimized GLP-1/GCG Agonist for Rapid Liver Fat Reduction Regardless of Body Weight Loss & Exploring Novel Approaches for Oral Peptide Delivery
Time: 11:30 am
day: Conference Day One
Details:
- Focusing on phase 1 clinical data of GLP-1/GCG treatment in obese/overweight patients with T2D and/or NASH
- Understanding the significance of rapid liver fat reduction in NAFLD/NASH patients with GLP-1/GCG dual agonists
- Introducing novel methods to orally deliver peptide drugs, improving ease of administration
